(NERV) Minerva Neurosciences, Inc. Business Model Canvas Research

Minerva Neurosciences, Inc. depends on FDA and other health agencies for feedback on study design, endpoints, and approval paths, while IRBs and ethics committees must clear each patient study. This matters even more after the FDA’s 2025 approval of 50 drugs, a reminder that regulator alignment is a gating step, not a formality.

• FDA review shapes trial design
• IRBs approve patient studies
• Endpoints drive future approval

Minerva Neurosciences, Inc. relies on manufacturing and analytical vendors to supply drug substance, formulation, and quality testing for its clinical-stage programs, including investigational use batches. This keeps fixed asset needs light, since the Company can scale external capacity instead of building heavy in-house manufacturing sites.

• Drug substance and formulation supplied externally
• Quality testing done by specialist vendors
• Supports investigational use supply
• Reduces in-house manufacturing spend

Intellectual property management is central for Minerva Neurosciences, Inc. because roluperidone and MIN-301 are the core assets that can still create value; without strong patent coverage and tight licensing terms, commercial optionality shrinks fast. For a small development-stage company with limited revenue, IP control is the main lever for partnering power and future upside.

Minerva Neurosciences, Inc. must closely oversee its Mitsubishi Tanabe partnership and outsourced vendors, since clinical work depends on disciplined partner governance and vendor control. It also has to protect cash for development, making financing a core operating task, not a side job.

• Manage Mitsubishi Tanabe coordination.
• Oversee outsourced service quality.
• Preserve cash for R&D funding.
• Keep financing needs in focus.

Minerva Neurosciences’ value hinges on deep CNS know-how, especially in schizophrenia and neurodegeneration, where endpoint choice and data reads can make or break a trial. In FY2025, this human capital stayed a core intangible resource because the Company remained a development-stage business with no broad commercial scale.

• 1 lead CNS development focus
• 2 key expertise areas: schizophrenia, neurodegeneration
• Expertise guides endpoints and data interpretation

Minerva Neurosciences, Inc. is headquartered in Waltham, Massachusetts, and that site anchors management, finance, and development oversight. As a clinical-stage Company with no commercial revenue in FY2025, its central office is the main control point for capital use and pipeline decisions.

• Waltham is the operating hub.
• Runs management and finance.
• Directs development oversight.

Minerva Neurosciences, Inc. uses the Mitsubishi Tanabe license to hold global roluperidone rights outside Asia, so it can push development and later market access without building a large internal commercial team. That partner-led setup is capital efficient because it shares execution load, lowers fixed cost needs, and keeps focus on a single late-stage asset.

• Global rights outside Asia
• Faster path to commercialization
• Lower internal scale needs

Schizophrenia affects about 24 million people worldwide, and Parkinson’s disease affects over 8.5 million, yet both still leave many patients without well-tolerated, durable treatment options. Minerva Neurosciences focuses on these hard-to-treat areas, so even modest efficacy or safety gains can create real clinical value and commercial upside.

• High unmet need in schizophrenia
• High unmet need in Parkinson’s disease
• Better therapies can add clear value

As a development-stage public biotech, Minerva Neurosciences, Inc. must keep investors updated on roluperidone progress, cash runway, and trial milestones, because access to financing depends on that trust. The key question is whether current cash can fund the next data readout without forcing a dilutive raise.

• Lead asset: roluperidone
• Focus: trial progress and milestones
• Watch item: cash runway
• Goal: preserve financing access

Patients in Minerva Neurosciences, Inc. studies interact mainly through clinical sites and study teams, so the relationship is tightly protocol-based. Informed consent, scheduled visits, and follow-up drive the contact model, and that discipline is what makes the clinical data credible.

• Site-led patient contact
• Consent before any study work
• Follow-up supports data quality

Minerva Neurosciences’ corporate website is its public information hub, with pipeline, governance, and company news for investors and stakeholders. In 2025, the site supported access to filings and updates on its lead CNS program, roluperidone, while the company reported a market cap below $100 million and ongoing clinical-stage operations.

• Pipeline updates and trial news
• Board, filings, and governance access
• Investor and stakeholder communication

SEC filings and investor decks are Minerva Neurosciences, Inc.'s main channels for reaching investors. That matters because the Company has no meaningful product revenue, so updates on cash, trial progress, and FDA plans come mainly through 10-Ks, 10-Qs, 8-Ks, and presentations.

• SEC filings: core financial updates
• Investor decks: clinical progress and strategy
• Key use: transparency without sales data

Hospitals and clinical centers are Minerva Neurosciences, Inc. key direct users in development because they host CNS trials, care for study participants, and generate the clinical evidence needed for FDA review. In 2025, Minerva reported $0 revenue and $21.8 million in cash and cash equivalents, so these sites remain core to preserving trial access and data quality.

• Host and run clinical trials
• Treat complex CNS patients
• Support evidence generation

Partner pharmaceutical companies are Minerva Neurosciences, Inc.’s B2B licensing customers, with Mitsubishi Tanabe named in the roluperidone deal. These partners can fund development, support commercialization, and extend Minerva’s reach across markets; that matters for a company with a reported cash balance of $14.6 million as of 31 March 2025.

In practice, Minerva uses these partners to turn one drug asset into broader geographic access without building a full sales force.

Minerva Neurosciences, Inc. must still fund management, finance, legal, audit, and SEC reporting, so general and administrative expense is a fixed overhead line even in a lean biopharma model. For a Waltham headquarters, these public-company costs can still reach the low-single-digit millions a year and protect the corporate shell while clinical spend is controlled.

• Management and finance overhead
• Legal, audit, and SEC filing costs
• Supports Waltham HQ operations

Minerva Neurosciences, Inc. carries recurring IP and partner-management costs because licensing, patent work, and contract oversight protect its deal rights and asset base. In its latest annual filing, the company reported no product revenue and continued operating losses, so these legal and collaboration controls stay a fixed cost of doing business.

• Licensing and legal review add steady overhead.
• Patent prosecution must keep running.
• Partner governance protects contract value.

Royalties on future sales of roluperidone could become Minerva Neurosciences, Inc.'s main long-term license income if the drug reaches market. This is a classic asset-licensing model: cash flow starts only after approval and scales with downstream sales, so Minerva’s revenue would track commercial uptake rather than one-time product sales.

• Triggered only after market launch
• Linked directly to net sales
• Low-risk, long-duration income stream

Minerva Neurosciences, Inc. has no current product sales, so future commercialization is still hypothetical. If MIN-301 or another asset clears clinical testing, FDA approval, and launch, direct product revenue could start later; until then, this stream is zero and depends on execution, funding, and time to market.

• Current product revenue: none
• Needs clinical success
• Needs regulatory approval
• Launch risk remains high